首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   679711篇
  免费   10665篇
  国内免费   2391篇
工业技术   692767篇
  2021年   5611篇
  2020年   4365篇
  2019年   5472篇
  2018年   25588篇
  2017年   25006篇
  2016年   20512篇
  2015年   7286篇
  2014年   10770篇
  2013年   28838篇
  2012年   20862篇
  2011年   35069篇
  2010年   29186篇
  2009年   28600篇
  2008年   29657篇
  2007年   31174篇
  2006年   17808篇
  2005年   19254篇
  2004年   17180篇
  2003年   16486篇
  2002年   14362篇
  2001年   13106篇
  2000年   12167篇
  1999年   12609篇
  1998年   30691篇
  1997年   21421篇
  1996年   16725篇
  1995年   13177篇
  1994年   11601篇
  1993年   11438篇
  1992年   8627篇
  1991年   8178篇
  1990年   8070篇
  1989年   7706篇
  1988年   7237篇
  1987年   6440篇
  1986年   6263篇
  1985年   7113篇
  1984年   6558篇
  1983年   6004篇
  1982年   5533篇
  1981年   5491篇
  1980年   5111篇
  1979年   5019篇
  1978年   4900篇
  1977年   5662篇
  1976年   7298篇
  1975年   4294篇
  1974年   3935篇
  1973年   4061篇
  1972年   3378篇
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
1.
The influence of the microstructure on the corrosion rate of three monolithic SiC samples in FLiNaK salt at 900 °C for 250 h was studied. The SiC samples, labeled as SiC-1, SiC-2, and SiC-3, had corrosion rates of 0.137, 0.020, and 0.043 mg/cm2h, respectively. Compared with grain size and the presence of special grain boundaries (i.e., Σ3), the content of high-angle grain boundaries (HAGBs) appeared to have the strongest influence on the corrosion rate of SiC in FLiNaK salt, since the corrosion rate increased six times as the concentration of high-angle grain boundaries increased from 19 to 32% for SiC-2 and SiC-1, respectively. These results stress the importance of controlling the content of HAGBs during the production process of SiC.  相似文献   
2.
The germline carrier of the BRCA1 pathogenic mutation has been well proven to confer an increased risk of breast and ovarian cancer. Despite BRCA1 biallelic pathogenic mutations being extremely rare, they have been reported to be embryonically lethal or to cause Fanconi anemia (FA). Here we describe a patient who was a 48-year-old female identified with biallelic pathogenic mutations of the BRCA1 gene, with no or very subtle FA-features. She was diagnosed with ovarian cancer and breast cancer at the ages of 43 and 44 and had a strong family history of breast and gynecological cancers.  相似文献   
3.
Heparanase (Hpse) is an endo-β-D-glucuronidase capable of cleaving heparan sulfate side chains. Its upregulated expression is implicated in tumor growth, metastasis and angiogenesis, thus making it an attractive target in cancer therapeutics. Currently, a few small molecule inhibitors have been reported to inhibit Hpse, with promising oral administration and pharmacokinetic (PK) properties. In the present study, a ligand-based pharmacophore model was generated from a dataset of well-known active small molecule Hpse inhibitors which were observed to display favorable PK properties. The compounds from the InterBioScreen database of natural (69,034) and synthetic (195,469) molecules were first filtered for their drug-likeness and the pharmacophore model was used to screen the drug-like database. The compounds acquired from screening were subjected to molecular docking with Heparanase, where two molecules used in pharmacophore generation were used as reference. From the docking analysis, 33 compounds displayed higher docking scores than the reference and favorable interactions with the catalytic residues. Complex interactions were further evaluated by molecular dynamics simulations to assess their stability over a period of 50 ns. Furthermore, the binding free energies of the 33 compounds revealed 2 natural and 2 synthetic compounds, with better binding affinities than reference molecules, and were, therefore, deemed as hits. The hit compounds presented from this in silico investigation could act as potent Heparanase inhibitors and further serve as lead scaffolds to develop compounds targeting Heparanase upregulation in cancer.  相似文献   
4.
5.
Catalysis Letters - We converted agro-waste Custard Apple Peels (CAP) to ash via thermal treatment, on which Pd(OAc)2 was immobilized easily that produced a low-cost, highly efficient Pd/CAP-ash...  相似文献   
6.
Nutrient Cycling in Agroecosystems - Reducing agriculturally derived diffuse contaminant losses (via non-point sources) from land to water has proven difficult for decades. Owing to the diversity...  相似文献   
7.
Atomic Energy - The physical aspects and main results of reactor tests of a two-stage core consisting of fresh fuel assemblies and a significant number of fuel assemblies from the previous core,...  相似文献   
8.
Journal of Communications Technology and Electronics - An option of multicriteria collision risk ranking of aircraft by data from an onboard radar station (OBRS) is proposed. This method can be...  相似文献   
9.
Protection of Metals and Physical Chemistry of Surfaces - Impedance spectroscopy was used to study the adsorption of the IFKhAN-92 inhibitor, a triazole derivative, on cathodically polarized...  相似文献   
10.
An improved glucose-chelator-albumin bioconjugate (GluCAB) derivative, GluCAB-2Mal, has been synthesized and studied for in vivo 64Cu-PET/CT imaging in breast cancer mice models together with its first-generation analogue GluCAB-1Mal. The radioligand works on the principle of tumor targeting through the enhanced permeability and retention (EPR) effect with a supportive role played by glucose metabolism. [64Cu]Cu-GluCAB-2Mal (99 % RCP) exhibited high serum stability with immediate binding to serum proteins. In vivo experiments for comparison between tumor targeting of [64Cu]Cu-GluCAB-2Mal and previous-generation [64Cu]Cu-GluCAB-1Mal encompassed microPET/CT imaging and biodistribution analysis in an allograft E0771 breast cancer mouse model. Tumor uptake of [64Cu]Cu-GluCAB-2Mal was clearly evident with twice as much accumulation as compared to its predecessor and a tumor/muscle ratio of up to 5 after 24 h. Further comparison indicated a decrease in liver accumulation for [64Cu]Cu-Glu-CAB-2Mal.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号